Mar. 1 at 10:34 AM
$PFE still moving — not dead yet Pfizer isn’t just a meme anymore. Shares ~
$27.6 and up on solid trading action (beat EPS, beat revenue on latest quarter).
Earnings showed strength vs expectations and the chart tried to break higher, but guidance remains mixed into ’26 as COVID franchise fades and revenue growth slows.
If this is helpful to you, tap @NasdaqKnight
Pharma overall is lagging, but PFE outperformed peers recently on a weak market day — signaling rotation into value plays.
Wall St consensus is still Hold, with moderate upside targets.
💡 Smart money mindset:
– Beat earnings = short‑term buzz
– Fundamentally still grappling with patent cliffs & sliding COVID sales
– Dividend yield + value narrative keep bulls interested
If you’re already full‑sized 🫡… watch key technical levels, next catalysts (earnings/clinical news), and whether value rotation continues.
